These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10071969)

  • 41. Secondary response of ovarian tumors to topotecan treatment.
    Dunton CJ; Neufeld J; Carlson JA
    Gynecol Oncol; 1998 Jun; 69(3):258-9. PubMed ID: 9648598
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of chemotherapy as palliative treatment for patients with advanced ovarian cancer.
    Markman M
    Semin Oncol; 1995 Apr; 22(2 Suppl 3):25-9. PubMed ID: 7537900
    [TBL] [Abstract][Full Text] [Related]  

  • 43. "Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?
    Markman M
    Gynecol Oncol; 1998 May; 69(2):91-2. PubMed ID: 9600812
    [No Abstract]   [Full Text] [Related]  

  • 44. [Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer].
    Edelman DZ; Anteby SO; Peretz T
    Harefuah; 1996 Jul; 131(1-2):31-6. PubMed ID: 8854476
    [No Abstract]   [Full Text] [Related]  

  • 45. How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?
    Ledermann JA; Wheeler S
    Cancer Invest; 2004; 22 Suppl 2():2-10. PubMed ID: 15573740
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.
    Bridgewater JA; Nelstrop AE; Rustin GJ; Gore ME; McGuire WP; Hoskins WJ
    J Clin Oncol; 1999 Feb; 17(2):501-8. PubMed ID: 10080591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Ovarian cancer-criteria of response and the timing of regimen change in chemotherapy for ovarian cancer].
    Takeuchi S; Takada A; Sugiyama T
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1471-6. PubMed ID: 23064058
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging therapeutic options for platinum-sensitive ovarian cancer patients.
    Armstrong DK; Coleman RL; Penson RT
    Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 5):1-16. PubMed ID: 21558997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management strategies for recurrent platinum-resistant ovarian cancer.
    Naumann RW; Coleman RL
    Drugs; 2011 Jul; 71(11):1397-412. PubMed ID: 21812505
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent advances in the treatment of epithelial ovarian cancer.
    Harries M; Kaye SB
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1715-24. PubMed ID: 11772280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Platinum or nonplatinum in recurrent ovarian cancer: that is the question.
    Poveda A; Marth C
    Future Oncol; 2017 Oct; 13(23s):11-16. PubMed ID: 29020823
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer.
    Malik IA
    Jpn J Clin Oncol; 2001 Feb; 31(2):69-73. PubMed ID: 11302345
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Salvage therapy for ovarian cancer.
    Sabbatini P; Spriggs D
    Oncology (Williston Park); 1998 Jun; 12(6):833-43; discussion 844-6, 848, 851. PubMed ID: 9644684
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Ovarian cancer--therapeutic options after the failure of the first line of treatment].
    Jabłońska E; Chłosta M; Pawlega J
    Ginekol Pol; 2004 Jan; 75(1):58-64. PubMed ID: 15112475
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.
    Lee CR; Faulds D
    Drugs; 1995 Jun; 49(6):932-53. PubMed ID: 7641606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First-line randomized trials: revisiting the Ptolemaic universe.
    Bookman MA
    Int J Gynecol Cancer; 2008; 18 Suppl 1():47-52. PubMed ID: 18336401
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Salvage therapy for ovarian cancer.
    Garcia AA
    Curr Oncol Rep; 1999 Sep; 1(1):64-70. PubMed ID: 11122800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients.
    Stinson TJ; Calhoun E; Yang T; Lurain JR; Bennett CL
    Cancer Invest; 1999; 17(8):559-65. PubMed ID: 10592762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral altretamine used as salvage therapy in recurrent ovarian cancer.
    Chan JK; Loizzi V; Manetta A; Berman ML
    Gynecol Oncol; 2004 Jan; 92(1):368-71. PubMed ID: 14751188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in the chemotherapy of gynecologic cancer.
    Neijt JP
    Curr Opin Oncol; 1994 Sep; 6(5):531-8. PubMed ID: 7827159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.